Eli Lilly’s tirzepatide (Mounjaro) won FDA approval to reduce cardiovascular risk in adults with type 2 diabetes at high risk for cardiovascular events. The approval is based on SURPASS-CVOT, the head-to-head cardiovascular outcomes trial comparing tirzepatide with dulaglutide, which reported an 8% lower rate of the composite MACE-3 outcome. The label expands beyond tirzepatide’s established glycemic and weight benefits, positioning the drug as a cardiovascular risk-reduction option for a large at-risk population. Lilly described the safety profile as consistent with the known tirzepatide tolerability pattern, with gastrointestinal adverse events prominent during dose escalation. For biotech and pharma, the decision reinforces the growing regulatory emphasis on cardiovascular outcomes in metabolic disease labels and increases competitive pressure across incretin-based platforms. It also raises the bar for payer discussions where CV benefit has become a key differentiator.